Calgary, AB – TheNewswire -- January 5, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news releases (November 20, December 1, December 11, and December 20, 2023), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 20, 2023, UI announced that it would delay the filing of [...]